Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
Patent
1995-04-21
1996-06-04
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
A61K 3165
Patent
active
055232973
ABSTRACT:
A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production is disclosed.
REFERENCES:
patent: 4666897 (1987-05-01), Golub et al.
patent: 4704383 (1987-11-01), McNamara et al.
patent: 4925833 (1990-05-01), Golub et al.
patent: 4935411 (1990-06-01), McNamara et al.
patent: 4935412 (1990-06-01), McNamara et al.
patent: 5045538 (1991-09-01), Schneider et al.
patent: 5258371 (1993-11-01), Golub et al.
patent: 5308839 (1994-05-01), Golub et al.
patent: 5459135 (1995-10-01), Golub et al.
Sugatani et al., "In Vitro Actions Of Some Antibiotics On Phospholipases", J. of Antibiotics 32: 734-739 (1979).
Pruzanski et al., "Phospholipase A.sub.2 --A Mediator Between Proximal And Distal Effectors Of Inflammation", Immuno. Today 12: 143-146 (1991).
Granstrom, "The Arachidonic Acid Cascade", Inflammation 8: S15-25 (1984, suppl 5).
O'Flaherty, "Lipid Mediators Of inflammation And Allergy", Lab. Invest. 47: 314-329 (1982).
Trang, "Prostaglandins And Inflammation", Sem. Arthritis Rheum. 9: 153-190 (1980).
Williams, "Interactions Between Prostaglandins, Leukotrienes And Other Mediators Of Inflammation", Br. Med. Bull. 39: 239-242 (1983).
Van den Bosch, "Intracellular Phospholipases A", Biochem. Biophys. Acta 604: 191-246 (1980).
Vadas et al., "Role Of Secretory Phospholipases A.sub.2 In The Pathobiology Of Disease", Lab. Invest. 55: 391-404 (1986).
Mizel, "The Interleukins", FASEB J. 3: 2379-2388 (1989).
Beutler et al., "Cachectin: More Than A Tumor Necrosis Factor", New Engl. J. Med. 316: 379-385 (1987).
Nathan et al., "Cytokines: Interferon-.gamma.", in Inflammation (Gallin et al. eds.) Raven Press 229-251 (1988).
Braquet et al., "Platelet-Activating Factor And Cellular Immune Responses", Immunol. Today 8: 345-352 (1987).
Marcus, "Eicosanoids: Transcellular Metabolism", in Inflammation (Gallin et al. eds.) Raven Press 129-137 (1988).
Wolpe et al., "Macrophage Inflammatory Proteins 1 And 2: Members Of A Novel Superfamily Of Cytokines", FASEB J. 3: 2565-2573 (1989).
Hsueh et al., "Two Phospholipase Pools For Prostaglandin Synthesis In Macrophages", Nature 290: 710-713 (1981).
Franson et al., "Isolation And Characterization Of A Phospholipase A.sub.2 From An Inflammatory Exudate", J. Lipid Res. 19: 18-23 (1978).
Gans et al., "Extracellular Phospholipase A.sub.2 Activity In Cell Free Peritoneal Lavage Fluid From Mice With Zymosan Peritonitis", Agents & Actions 27: 341-343 (1989).
Vadas et al., "Involvement Of Circulating Phospholipase A.sub.2 In The Pathogenesis Of The Hemodynamic Changes In Endotoxin Shock", Can. J. Physiol. Pharmacol. 61: 561-566 (1983).
Marsh et al., "The Effects Of Honey Bee (Apis mellifera L.) Venom And Two Of Its Constituents, Melittin And Phospholipase A.sub.2 On The Cardiovascular System Of The Rat", Toxicon. 18: 427-435 (1980).
Huang et al., "Relaxant Effect Of Phospholipase A.sub.2 From Vipera russelli Snake Venom On Rat Aorta", Eur. J. Pharmacol. 118: 139-146 (1985).
Morgan et al., "Phospholipids, Acute Pancreatitis, And The Lungs: Effect Of Lecithinase Infusion On Pulmonary Surface Activity In Dogs", Ann. Surg. 167: 329-335 (1968).
Stommer et al., "Phospholipase A.sub.2 Induced Diffuse Aleolar Damage--Effect Of Indomethacin And Dexamethasone Upon Morphology And Plasma-Histamine Level", Klin. Wochenschr. 67: 171-176 (1989).
Shaw et al., "Phospholipase A.sub.2 Contamination Of Cobra Venom Factor Preparations", Am. J. Pathol. 91: 517-530 (1978).
Vadas et al., "Extracellular Phospholipase A.sub.2 Mediates Inflammatory Hyperaemia", Nature 293: 583-585 (1981).
Pruzanski et al., "Inflammatory Effect Of Intradermal Administration Of Soluble Phospholipase A.sub.2 In Rabbits", J. Invest. Dermatol. 86, 380-383 (1986).
Vadas et al., "The Proinflammatory Effect Of Intra-Articular Injection Of Soluble Human And Venom Phospholipase A.sub.2 ", Am. J. Pathol. 134: 807-811 (1989).
Vishwanath et al., "Edema-Inducing Activity Of Phospholipase A.sub.2 Purified From Human Synovial Fluid And Inhibition By Aristolochic Acid", Inflammation 12: 549-561 (1988).
Cirino et al., "A Study Of Phospholipase A.sub.2 -Induced Oedema In Rat Paw", Eur. J. Pharmacol. 166: 505-510 (1989).
Pruzanski et al., "Phospholipase A.sub.2 Activity In Sera And Synovial Fluids In Rheumatoid Arthritis And Osteoarthritis. Its Possible Role As A Proinflammatory Enzyme", J. Rheumatol. 12: 211-216 (1985).
Vadas et al., "Phospholipases A.sub.2 In Acute Bacterial Peritonitis In Man", in Cell Activation and Signal Initiation (Dennis et al., eds.) Alan R. Liss 311-316 (1989).
Vadas et al., "Pathogenesis Of Hypotension In Septic Shock: Correlation Of Circulating Phospholipase A.sub.2 Levels With Circulatory Collapse", Crit. Care Med. 16: 1-7 (1988).
Vadas, "Elevated Plasma Phospholipase A.sub.2 Levels: Correlation With The Hemodynamic And Pulmonary Changes In Gram-Negative Septic Shock", J. Lab. Clin. Med. 104: 873-881 (1984).
Jakobsen, et al., "Demonstration Of Soluble Plasmodium falciparum Antigens Reactive With Limulus Amoebocyte Lysate And Polymyxin B", Parasite Immunol. 10: 593-606 (1988).
Clark, "Does Endotoxin Cause Both The Disease And Parasite Death In Acute Malaria And Babesiosis?", Lancet ii: 75-77 (1978).
Ehrlich, "Erosive Inflammatory And Primary Generalized Osteoarthritis", in Osteoarthritis, Diagnosis, and Management (Moskowitz et al., eds.) W. B. Saunders Co. 199-209 (1984).
Revell et al., "The Synovial Membrane In Osteoarthritis: A Histological Study Including The Characterization Of The Cellular Infiltrate Present In Inflammmatory Osteoarthritis Using Monoclonal Antibodies", Ann. Rheum. Dis. 47: 300-307 (1988).
Pelletier et al., "Evidence For The Involvement Of Interleukin 1 In Human Osteoarthritic Cartilage Degradation: Protective Effect Of NSAID", J. Rheumatol. 16: (Suppl. 18) 19-27 (1989).
Shinmei et al., "The Role Of Cytokines In Chondrocyte Mediated Cartilage Degradation", J. Rheumatol. 16: (Suppl. 18) 32-34 (1989).
Mitscher, "Chemical Transformations Of The Tetracycline Family", in The Chemistry of Tetracyclines, Chapter 6, Marcel Dekker, Publishers, N.Y. (1978).
Golub et al., "Further Evidence That Tetracyclines Inhibit Collagenase Activity In Human Crevicular Fluid And Form Other Mammalian Sources", J. Periodont. Res. 20: 12-23 (1985).
Golub et al., "Tetracyclines Inhibit Connective Tissue Breakdown: New Therapeutic Implications For An Old Family of Drugs", Crit. Revs. Oral Biol. & Med. 2: 297-322 (1991).
Golub et al., "Tetracyclines (TCs) Inhibit Matrix Metalloproteinases (MMPs): In Vivo Effects In Arthritic And Diabetic Rats, And New In Vitro Studies," Matrix, Suppl. No. 1: 315-316 (1992).
Sipos et al., "The Effect Of Collagenase Inhibitors On Alveolar Bone Loss Due To Periodontal Disease In Desalivated Rats," abstract presented at Matrix Metalloproteinase Conference, Destin, Florida, Sep. 11-15, (1989).
Greenwald et al. "CMT, A Metalloproteinase Inhibitor, Prevents Bone Resorption In Adjuvant Arthritis." Arthritis Rheum. 34 (#9 suppl): S66 (abstract #A6), abstract presented at 55th Annual Meeting, Amer. College of Rheumatology, Boston MA, Nov. 18, (1991).
Breedveld, "Suppression Of Collagen And Adjuvant Arthritis By A Tetracycline," Northeastern Regional Meeting Of The Amer. Rheum. Assoc., Atlantic City, New Jersey, Oct. 23-24, 1987.
Skinner et al., "Tetracycline In The Treatment Of Rheumatoid Arthritis", Arthritis and Rheumatism 14; 727-732 (1971).
Greenwald et al., "Tetracyclines Inhibit Human Synovial Collagenase In Vivo and In Vitro", J. Rheumatol. 14: 28-32 (1987).
Breedveld, "Minocycline Treatment For Rheumatoid Arthritis: An Open Dose Finding Study", J. Rheumat. 17: 43-46 (1990).
Wong et al., "Oral Ibuprofen And Tetracycline For The Treatment Of Acne Vulgaris", Journal of American Academy of Dermatology 11: 1076-1081 (1984).
Funt, "Oral Ibuprofen And Minocycline For The Treatment Of Resistant Acne Vulgaris", Journal of the American Academy of Dermatology 13:
Golub Lorne M.
Greenwald Robert A.
McNamara Thomas F.
Pruzanski Waldemar
Ramamurthy Nangavarum S.
Cintins Marianne M.
Jarvis William R. A.
The Research Foundation of State University of New York
LandOfFree
Inhibition of excessive phospholipase A.sub.2 activity and/or pr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of excessive phospholipase A.sub.2 activity and/or pr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of excessive phospholipase A.sub.2 activity and/or pr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-383446